Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
07
2022
accepted:
28
12
2022
entrez:
17
1
2023
pubmed:
18
1
2023
medline:
20
1
2023
Statut:
epublish
Résumé
The immune system plays a central role in the onset and progression of cancer. A better understanding of transcriptional changes in immune cell-related genes associated with cancer progression, and their significance in disease prognosis, is therefore needed. NanoString-based targeted gene expression profiling has advantages for deployment in a clinical setting over RNA-seq technologies. We analysed NanoString PanCancer Immune Profiling panel gene expression data encompassing 770 genes, and overall survival data, from multiple previous studies covering 10 different cancer types, including solid and blood malignancies, across 515 patients. This analysis revealed an immune gene signature comprising 39 genes that were upregulated in those patients with shorter overall survival; of these 39 genes, three (MAGEC2, SSX1 and ULBP2) were common to both solid and blood malignancies. Most of the genes identified have previously been reported as relevant in one or more cancer types. Using Cibersort, we investigated immune cell levels within individual cancer types and across groups of cancers, as well as in shorter and longer overall survival groups. Patients with shorter survival had a higher proportion of M2 macrophages and γδ T cells. Patients with longer overall survival had a higher proportion of CD8+ T cells, CD4+ T memory cells, NK cells and, unexpectedly, T regulatory cells. Using a transcriptomics platform with certain advantages for deployment in a clinical setting, our multi-cancer meta-analysis of immune gene expression and overall survival data has identified a specific transcriptional profile associated with poor overall survival.
Identifiants
pubmed: 36649303
doi: 10.1371/journal.pone.0280364
pii: PONE-D-22-19319
pmc: PMC9844904
doi:
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0280364Subventions
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
F1000Res. 2016 Jun 20;5:1438
pubmed: 27508061
Sci Rep. 2013 Oct 02;3:2652
pubmed: 24084870
Chin J Cancer Res. 2019 Jun;31(3):463-470
pubmed: 31354215
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31727782
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
Sci Rep. 2021 Nov 2;11(1):21504
pubmed: 34728682
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31618839
BMC Med Genomics. 2020 Apr 3;13(Suppl 5):41
pubmed: 32241264
PLoS One. 2011;6(6):e21418
pubmed: 21738656
Biomed Res Int. 2018 Sep 18;2018:2109865
pubmed: 30320132
Future Sci OA. 2020 Nov 25;7(2):FSO662
pubmed: 33437521
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
Front Immunol. 2019 Jan 29;10:14
pubmed: 30761123
Cancer Immunol Res. 2019 Nov;7(11):1813-1823
pubmed: 31484657
Eur J Cancer. 2006 Apr;42(6):717-27
pubmed: 16520032
J Exp Clin Cancer Res. 2019 Dec 9;38(1):485
pubmed: 31818309
J Immunother Cancer. 2017 May 16;5:44
pubmed: 28515944
Blood Adv. 2018 Sep 11;2(17):2242-2252
pubmed: 30194138
Onco Targets Ther. 2015 Oct 22;8:3095-104
pubmed: 26543378
Clin Cancer Res. 2012 Feb 1;18(3):713-25
pubmed: 22186257
Clin Cancer Res. 2020 Aug 15;26(16):4313-4325
pubmed: 32430479
Cancer Manag Res. 2019 Nov 12;11:9571-9583
pubmed: 31814759
Nat Commun. 2021 Jan 19;12(1):444
pubmed: 33469002
Oncol Lett. 2020 Jan;19(1):93-102
pubmed: 31897119
Eur J Cancer. 2019 Jul;116:67-76
pubmed: 31173964
Nat Rev Cancer. 2016 Mar;16(3):131-44
pubmed: 26911188
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
J Immunother Cancer. 2019 Feb 6;7(1):34
pubmed: 30728081
Genome Med. 2021 Apr 16;13(1):60
pubmed: 33863341
J Pineal Res. 2019 Apr;66(3):e12557
pubmed: 30638277
Immunogenetics. 2020 Dec;72(9-10):455-465
pubmed: 33188484
Int J Ayurveda Res. 2010 Oct;1(4):274-8
pubmed: 21455458
Reprod Biomed Online. 2021 Dec;43(6):1045-1056
pubmed: 34627683
Oncol Lett. 2017 Mar;13(3):1609-1618
pubmed: 28454298
Sci Rep. 2021 Mar 15;11(1):6047
pubmed: 33723286
DNA Repair (Amst). 2019 Jun;78:142-153
pubmed: 31054516
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32376723
Exp Mol Med. 2021 Mar;53(3):318-327
pubmed: 33707742
Curr Cancer Drug Targets. 2017;17(8):682-697
pubmed: 28460617
Biomedicines. 2018 Feb 02;6(1):
pubmed: 29393888
Cancer Manag Res. 2021 Nov 16;13:8629-8646
pubmed: 34824550
Gastroenterology. 2019 May;156(6):1731-1741
pubmed: 30738047
Brief Bioinform. 2021 May 20;22(3):
pubmed: 32814346
Curr Opin Immunol. 2013 Apr;25(2):261-7
pubmed: 23579076
Am J Surg. 2016 Jan;211(1):142-51
pubmed: 26321295
Cancers (Basel). 2020 Jul 27;12(8):
pubmed: 32726984
Haematologica. 2011 Nov;96(11):1662-9
pubmed: 21791470
Cancer Immunol Immunother. 2021 Jul;70(7):2035-2048
pubmed: 33420630
Theranostics. 2018 Nov 12;8(21):5842-5854
pubmed: 30613266
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
J Immunol. 2012 Jan 15;188(2):703-13
pubmed: 22174445
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2900-9
pubmed: 25991856
Clinics (Sao Paulo). 2011;66(11):1879-86
pubmed: 22086517
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Cancers (Basel). 2020 Sep 01;12(9):
pubmed: 32882873
J Mol Diagn. 2020 May;22(5):685-698
pubmed: 32173570
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Nat Commun. 2019 Aug 28;10(1):3874
pubmed: 31462678
PLoS One. 2020 Mar 26;15(3):e0230536
pubmed: 32214348
Onco Targets Ther. 2019 Sep 24;12:7843-7855
pubmed: 31576142
Bioinformatics. 2020 Jul 1;36(Suppl_1):i389-i398
pubmed: 32657401
Cancers (Basel). 2022 Aug 10;14(16):
pubmed: 36010856
Medicine (Baltimore). 2017 Apr;96(15):e6472
pubmed: 28403077
Curr Opin Chem Eng. 2018 Mar;19:9-20
pubmed: 29623254
Front Cell Dev Biol. 2021 Nov 08;9:748039
pubmed: 34820376
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Cell Physiol. 2015 Nov;230(11):2598-605
pubmed: 25913194
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Curr Treat Options Oncol. 2017 May;18(5):32
pubmed: 28474265
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Eur J Cancer. 2017 May;77:3-12
pubmed: 28347920
Cancer Med. 2021 Jul;10(13):4629-4643
pubmed: 34121340
Dis Markers. 2021 Nov 08;2021:7711151
pubmed: 34790279
BMC Immunol. 2019 Jan 11;20(1):4
pubmed: 30634925
Nat Rev Cancer. 2021 Jun;21(6):345-359
pubmed: 33837297
Cancer Immunol Immunother. 2020 Sep;69(9):1905-1916
pubmed: 32377818
Blood. 2006 Mar 1;107(5):1955-62
pubmed: 16210338
BMC Cancer. 2021 Nov 21;21(1):1256
pubmed: 34802433
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Immunooncol Technol. 2019 Jun 26;1:3-10
pubmed: 35755322
PeerJ. 2021 Jan 15;9:e10746
pubmed: 33520474
Oncoimmunology. 2019 May 25;8(8):1614858
pubmed: 31413922
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Oncotarget. 2016 Oct 25;7(43):70092-70099
pubmed: 27602753
Sci Rep. 2015 Jun 03;5:10438
pubmed: 26039282
Cancer Cell Int. 2021 Sep 26;21(1):516
pubmed: 34565373
Pharmacol Res. 2022 Jan;175:105997
pubmed: 34826600
Cancer Immunol Immunother. 2013 Jan;62(1):191-5
pubmed: 23180015
Antibodies (Basel). 2020 Oct 25;9(4):
pubmed: 33113844
J Biol Methods. 2020 Jan 03;7(1):e123
pubmed: 31976350
Oncogene. 2017 Sep 7;36(36):5199-5211
pubmed: 28504716
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32719094
Front Oncol. 2018 Jul 06;8:264
pubmed: 30035102
BMC Genomics. 2017 Jul 3;18(1):508
pubmed: 28673244
Cancer Sci. 2012 Aug;103(8):1405-13
pubmed: 22587355
Cancer. 2018 Feb 15;124(4):785-796
pubmed: 29112225
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cancer Med. 2020 Jul;9(13):4791-4807
pubmed: 32383556
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Hematol Oncol. 2021 Apr;39(2):205-214
pubmed: 33215701
Front Oncol. 2021 Oct 18;11:755668
pubmed: 34733790
Int J Mol Sci. 2020 Aug 20;21(17):
pubmed: 32825489
PLoS One. 2019 Aug 5;14(8):e0219566
pubmed: 31381571
Cancers (Basel). 2019 Dec 05;11(12):
pubmed: 31817531
Clin Cancer Res. 2020 Jan 15;26(2):373-383
pubmed: 31645353
Cancer Immunol Immunother. 2009 May;58(5):641-52
pubmed: 18791713
J Pathol. 2018 Apr;244(5):512-524
pubmed: 29288495
Cancer Res. 2017 Jul 1;77(13):3540-3550
pubmed: 28487385
Cancer Res. 2011 Nov 1;71(21):6785-95
pubmed: 21880588
Sci Rep. 2019 Sep 13;9(1):13239
pubmed: 31519974
Front Pharmacol. 2021 Oct 19;12:728420
pubmed: 34744715
BMC Cancer. 2022 Feb 12;22(1):166
pubmed: 35151264
PLoS One. 2011;6(7):e21366
pubmed: 21754986
Nat Genet. 2016 Jul;48(7):725-32
pubmed: 27240091
Biosci Rep. 2019 May 17;39(5):
pubmed: 30992388